Your browser doesn't support javascript.
loading
Analysis of fomepizole safety based on a 16-year post-marketing experience in France.
Rasamison, Riana; Besson, Hélène; Berleur, Marie-Pierre; Schicchi, Azzurra; Mégarbane, Bruno.
Affiliation
  • Rasamison R; AGEPS, Pharmaceutical Establishment of Paris Hospitals, APHP, Paris, France.
  • Besson H; AGEPS, Pharmaceutical Establishment of Paris Hospitals, APHP, Paris, France.
  • Berleur MP; AGEPS, Pharmaceutical Establishment of Paris Hospitals, APHP, Paris, France.
  • Schicchi A; Department of Medical and Toxicological Critical Care, Federation of Toxicology APHP, Lariboisière Hospital, University of Paris, Paris, France.
  • Mégarbane B; Poison Control Centre and National Toxicology Information Centre - Toxicology Unit, Istituti Clinici Scientifici Maugeri, IRCCS Maugeri Hospital and University of Pavia, Pavia, Italy.
Clin Toxicol (Phila) ; 58(7): 742-747, 2020 07.
Article in En | MEDLINE | ID: mdl-31608703
ABSTRACT

Introduction:

Fomepizole has been recommended as first-line antidote to treat ethylene glycol and methanol poisoning. Despite more than 30 years of utilization, the safety of fomepizole when used clinically has not been well documented. Based on the long-standing clinical experience with fomepizole in France, we investigated its safety profile in patients treated for suspected toxic alcohol poisoning.

Methods:

We designed a 16-year post-marketing study to evaluate the indications for fomepizole prescriptions and to investigate its safety. Data were retrospectively collected using a standardized questionnaire sent each month by post to each French hospital that ordered fomepizole during the month before. The response rate to our survey was 59%.

Results:

Five hundred and thirty-six patients [188 females/348 males; age, 46 years [34-55] (median [25th-75th percentiles])] were treated with fomepizole [cumulative dose, 18.6 mg/kg [15.5-26.3] (1,268 mg [900-2,100])]. Ethylene glycol/methanol poisoning was confirmed in 275 patients (51%) while a nontoxic exposure was diagnosed in 147 patients (27%). Toxic alcohol poisoning was misdiagnosed in the remaining 114 patients (21%), before the assessment of an alternative poisoning or non-poisoning diagnosis. Fifty adverse reactions were attributed to fomepizole in 36 patients (7%) including general reactions (N = 22), local reactions (N = 22) and laboratory test impairments (N = 6). All were considered mild and transient. None required stopping fomepizole. The most frequent adverse effects were injection site pain/burning (N = 13), nausea/vomiting (N = 8), vessel puncture site inflammation (N = 7), drowsiness/confusion (N = 5) and serum aminotransferase elevation (N = 3). None of the fatalities (N = 37, 7%) or persistent symptoms on discharge (N = 9; 2%) was related to fomepizole.

Conclusion:

Our longitudinal cohort study supports the safety of fomepizole administered to treat presumed EG and methanol poisoning.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Poisoning / Product Surveillance, Postmarketing / Fomepizole / Antidotes Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Clin Toxicol (Phila) Journal subject: TOXICOLOGIA Year: 2020 Document type: Article Affiliation country: Francia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Poisoning / Product Surveillance, Postmarketing / Fomepizole / Antidotes Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Clin Toxicol (Phila) Journal subject: TOXICOLOGIA Year: 2020 Document type: Article Affiliation country: Francia